CTOs on the Move

Bridge Credit Union

www.bridgecu.org

 
For 50+ years, Bridge has served our membership. *Links are not an endorsement by Bridge; we bear no responsibility for content on external sites.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.bridgecu.org
  • 1980, West Broad Street
    Columbus, OH USA 43223
  • Phone: 800.434.7300

Executives

Name Title Contact Details

Similar Companies

IBT Media

IBT Media is a fast-growing digital media and technology company based in New York City. The company started in 2006 when Etienne Uzac and Johnathan Davis launched the International Business Times (ibt.com), a digital news publication covering the world economy through several in-country and in-language editions. Today IBT Media owns and operates 13 digital properties divided into 3 groups (consumer, business and technology) in various verticals including business, tech, health and hispanic. IBT Media reaches over 20 million unique visitors a month and operates from its headquarters in downtown New York City.

AsburyUSA

AsburyUSA is a Pismo Beach, CA-based company in the Software and Internet sector.

Tri-State Business Group

Tri-State Business Group is a Newburgh, IN-based company in the Software and Internet sector.

Aujas

Aujas Cybersecurity Limited formerly known as Aujas Networks Private Limited is a global IT risk management company with a presence in United States, South Asia and the Middle East.

Kapost

Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.